| |
|
The development of OMT's fully human monoclonal antibody platform has
three major milestones. The generation of: (1) light chain transgenic animals, (2) heavy chain transgenic animals,
and (3) knockout rats with inactivated immunoglobulin loci.
OMT has created transgenic rats to serve as founders (F0) for the human light chain immunoglobulin (LC F0). At the end of 2008,
OMT generated knock-out rats with mutated immunoglobulin heavy chain loci (KO F0). This milestone is featured in "Knockout Rats
Produced via Embryo Microinjection of Designed Zinc Finger Nucleases" in the July 24th issue of "Science". OMT is crossing these lines for homozygosity. In the second half of 2009, OMT will generate founder rats with transgenic heavy-chain immunoglobulin
loci (HC F0). Then, it will cross these founders with LC/KO animals and begin development of monoclonal antibodies. In late 2009, OMT will consider partnering with a limited number of companies interested in its human antibody platform.
|
|
|
